Insulet Corporation

NasdaqGS PODD

Insulet Corporation Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 902.60 M

Insulet Corporation Cash and Short-Term Investments is USD 902.60 M for the quarter ending September 30, 2024, a 31.69% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Insulet Corporation Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 685.40 M, a -5.07% change year over year.
Insulet Corporation Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 722.00 M, a -15.76% change year over year.
Insulet Corporation Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 857.10 M, a -4.42% change year over year.
Insulet Corporation Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 896.70 M, a 48.09% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: PODD

Insulet Corporation

CEO	Dr. James R. Hollingshead Ph.D.
IPO Date	May 15, 2007
Location	United States
Headquarters	100 Nagog Park
Employees	3,000
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years